27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Plasma amyloid-β (Aβ)42, phosphorylated tau (p-tau)181, and neurofilament light chain (NfL) are promising biomarkers of Alzheimer's disease (AD). 2 key findings →
Participants: 126 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Plasma p-tau is a stronger indicator of a temporally linked response to elevated brain Aβ than of tau pathology. 4 key findings →
Participants: 1,408 Evidence: low
Full summary, score breakdown and related studies → Original source
Longitudinal multimodal biomarker studies reveal that the continuum of Alzheimer's disease (AD) includes a long latent phase, referred to as preclinical AD, which precedes the onset of symptoms by decades. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) pathology is thought to progress from normal cognition through preclinical disease and ultimately to symptomatic AD with cognitive impairment. 3 key findings →
Design: cross-sectional Participants: 164 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We found non-significant differences in age (F(2, 141) = 1.304; P = 0.275) and years of education (F(2, 141) = 0.013; P = 0.987). 5 key findings →
Design: cross-sectional Participants: 29 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Six patients with AD with GSN P3fs and K346fs mutations (0.50%, 6/1192) were identified, who were diagnosed with AD but not FAF. 5 key findings →
Participants: 1,192 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Physical activity moderated the association between MTA and plasma Aβ42/40 level and increased dementia risk. 5 key findings →
Participants: 1,044 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Vascular risk significantly predicted cerebral amyloid burden in Alzheimer's Disease Neuroimaging Initiative but not in the UCD-ADRC cohort. 5 key findings →
Design: cross-sectional Participants: 96 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The primary outcome is change in plasma p-tau181 concentration between baseline and following 180 days of treatment, which will be compared between the active and placebo group. 3 key findings →
Participants: 60 Evidence: high
Full summary, score breakdown and related studies → Original source
Among the 130 articles included in the review, 103 were cognitive training interventions (79%) and 27 were multimodal interventions (21%). 5 key findings →
Participants: 60 Evidence: high
Full summary, score breakdown and related studies → Original source
Previous studies have demonstrated resilience to AD-related neuropathology in a form of cognitive reserve (CR). 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
After ≤15 years, 5,491 all-cause dementia cases were diagnosed. 5 key findings →
Participants: 323,483 Evidence: low
Full summary, score breakdown and related studies → Original source
Compared with food secure older adults, those reporting food insecurity experienced worsened cognitive functioning over time (B = -0.63, p < .001), and they were more likely to have onset of cognitive impairment (OR= 1.46, p < .001) in the 6-y observation. 5 key findings →
Participants: 6,638 Evidence: low
Full summary, score breakdown and related studies → Original source
Gaining insight into the downstream consequences of non-coding variants is an essential step towards the identification of therapeutic targets from genome-wide association study (GWAS) findings. 4 key findings →
Participants: 31,684 Evidence: low
Full summary, score breakdown and related studies → Original source
Slow paced breathing via heart rate variability (HRV) biofeedback stimulates vagus-nerve pathways that counter noradrenergic stress and arousal pathways that can influence production and clearance of Alzheimer's disease (AD)-related proteins. 2 key findings →
Participants: 108 Evidence: high
Full summary, score breakdown and related studies → Original source
Unlike previous research that used traditional immunoassay, recent studies that measured plasma Aβ42/40 using fully automated platforms reported promising results. 3 key findings →
Participants: 174 Evidence: moderate
Full summary, score breakdown and related studies → Original source
While plasma biomarkers for Alzheimer's disease (AD) are increasingly being evaluated for clinical diagnosis and prognosis, few population-based autopsy studies have evaluated their utility in the context of predicting neuropathological changes. 3 key findings →
Participants: 350 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The MIND and Mediterranean diets are associated with less postmortem AD pathology, primarily β-amyloid load. 5 key findings →
Participants: 581 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This randomized controlled trial aims to investigate the effect of 12 weeks of therapeutic exercise on cognitive function and daily activities in patients with mild Alzheimer's disease (AD). 4 key findings →
Design: randomized controlled trial Participants: 57 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Fourteen- and 16-second cut points for the CST are suitable to identify people at higher risk of functional decline among older adults in Mexico and Toledo, Spain. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The S@H study is the first randomized trial of a firearm safety decision aid for ADRD caregivers. 3 key findings →
Design: randomized controlled trial Participants: 117 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Once-weekly 5-mg/d donepezil TDS demonstrated minimal skin irritation under conditions of use of 3 consecutive weekly patch applications to the same skin site and minimal sensitization potential. 2 key findings →
Design: clinical trial Participants: 198 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Microglia activation is observed in various neurodegenerative diseases. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Disease-modifying drug use necessitates better Alzheimer disease (AD) detection. 4 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Epilepsy has been associated with cognitive impairment and potentially dementia in older individuals. 4 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →